



IMMUNOVIA INVITES TO A PRESENTATION ON THE Q1 REPORT AND 2026 OBJECTIVES

Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, will publish its interim report for January–March 2026 on Thursday, May 7th, at 8.30 CEST. A webcast presentation and conference call will be held on the same day at 15.00 CEST. The presentation will be co-hosted by Peter Høngaard Andersen, Chairman of the Board and Jeff Borderching, CEO and President.

The conference call will cover key events during the quarter, as well as the company's strategic direction and objectives for 2026. The presentation will be held in English and will be followed by a Q&A session.

Welcome to join via webcast or phone. Please dial in a few minutes before the presentation begins.

Webcast:

<https://creo-live.creomediamanager.com/d65d7d7f-Obd0-41f5-ba49-4f5d6d80ff75>

Number for dial-in participants:

Sweden: +46 (0)8 5051 0031

United Kingdom: +44 (0) 207 107 06 13

United States: +1 (1) 631 570 56 13

The report, together with the presentation slides, will be available at www.immunovia.com.

For more information, please contact:

Jeff Borcharding

CEO and President

jeff.borcharding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit. www.immunovia.com.